Long-term safety and efficacy of aliskiren and valsartan combination with or without the addition of HCT in patients with hypertension

Current Medical Research and Opinion

Volumn 26, Issue 12, 2010, Pages 2841-2849

  Chrysant, Steven G ^a   Murray, Alexander V ^b   Hoppe, Uta C ^c   Dattani, Dan ^d   Patel, Samir ^e   Ritter, Shannon ^e   Zhang, Jack ^e  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b PharmQuest   (United States)

^c UNIVERSITY OF COLOGNE   (Germany)

^d UNIVERSITY OF SASKATCHEWAN   (Canada)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Aliskiren; Direct renin inhibition; Hyperkalemia; Hypertension; Valsartan

Indexed keywords

ALISKIREN; HYDROCHLOROTHIAZIDE; POTASSIUM; VALSARTAN;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; BRONCHITIS; CLINICAL TRIAL; COUGHING; DIARRHEA; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERKALEMIA; HYPERTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; POTASSIUM BLOOD LEVEL; RHINOPHARYNGITIS; SINUSITIS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; AMIDES; ANTIHYPERTENSIVE AGENTS; DRUG COMBINATIONS; DRUG TOXICITY; FEMALE; FOLLOW-UP STUDIES; FUMARATES; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; INCIDENCE; MALE; MIDDLE AGED; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; VALINE; YOUNG ADULT;

EID: 78349260796     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.528282     Document Type: Article

References (29)

1. Xie F, Petitti DB, Chen W. Prescribing patterns for antihypertensive drugs after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: report of experience in a health maintenance organization. Am J Hypertens 2005;18:464-9
2. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-28
3. Messerli FH. The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point. J Am Coll Cardiol 2009; 53:468-70
4. Israili ZH, Hernandez-Hernandez R, Valasco M. The future of antihypertensive treatment. Am J Ther 2007;14:121-34
5. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72
6. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004;43:10-17
7. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87
8. Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007;49:69-75
9. Fisher ND, Hollenberg NK. Is there a future for renin inhibitors? Expert Opin Investig Drugs 2001;103:417-26
10. Azizi M, Menard J. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation 2004;109:2492-9
11. Fisher ND, Hollenberg NK. Renin inhibition: what are the therapeutic opportunities? J Am Soc Nephrol 2005;16:592-9
12. Alderman MH, Ooi WL, Cohen H, et al. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am J Hypertens 1997;10:1-8
13. Bair TL, May HT, Prescott MF, et al. Association between baseline levels of plasma renin activity and risk of cardiovascular events. J Am Coll Cardiol 2009; 53(10 Suppl A), A383, Abstract 1028-12
14. Jacobsen P, Andersen S, Rossing K, et al. Dual blockade of the renin-angio-tensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 2003;63:1874-80
15. Fujisawa T, Ikegami H, Ono M, et al. Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy. Am J Hypertens 2005;18:13-17
16. Jennings DL, Kalus JS, Coleman CI, et al. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diabet Med 2007;24:486-93
17. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59
18. Pool JL. Direct renin inhibition: focus on aliskiren. J Manag Care Pharm 2007;13(8 Suppl B):21-33
19. Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007;370:221-9
20. Chrysant SG, Murray AV, Hoppe CU, et al. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis. Curr Med Res Opin 2008;24:1039-47
21. Frohlich ED, Carlene Grim C, Labarthe DR, et al. Recommendations for human blood pressure determination by sphygmomanometers: report of a special task force appointed by the Steering Committee, American Heart Association. Hypertension 1988;11:210-22A
22. Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007;20:11-20
23. Yarows SA, Oparil S, Patel S, et al. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study. Adv Ther 2008;25:1288-302
24. Brown MJ. Renin: friend or foe? Heart 2007;93:1026-33
25. Sureshkumar KK, Vasudevan S, Marcus RJ, et al. Aliskiren: clinical experience and future perspectives of renin inhibition. Expert Opin Pharmacother 2008;9:825-37
26. Vaidyanathan S, Valencia J, Kemp C, et al. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochloro-thiazide (HCTZ) and ramipril in healthy volunteers. Int J Clin Pract 2006; 60:1343-56
27. Vaidyanathan S, Bartlett M, Dieterich HA, et al. Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjects. Cardiovasc Ther 2008;26: 238-46
28. Pitt B. Aldosterone blockade in patients with acute myocardial infarction. Circulation 2003;107:2525-7
29. Iraqi W, Rossignol P, Angioi M, et al. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation 2009;119:2471-9